

# THE GOVERNMENT PHARMACEUTICAL ORGANIZATION

## RAW MATERIAL SPECIFICATION

|   |                                  |
|---|----------------------------------|
| <b>Title :</b> Furosemide USP (For injection dosage form) (Item No. 41032020) | <b>Spec. No. :</b> SP-AK30-F14/1 |
| <b>Reference(s) :</b> USP 39 p. 4059-4060                                     | <b>Rev. No. :</b> 06             |
| <b>Other Requirements :</b> GPO Specification                                 | <b>Page :</b> 1/3                |

### USP 39

| Test Items                       | Specification  |                       |
|----------------------------------|--|-----------------------|
| Description                      | White to slightly yellow, odorless, crystalline powder.  |                       |
| Solubility                       | Freely soluble in acetone, in dimethylformamide, and in solutions of alkali hydroxides; soluble in methanol; sparingly soluble in alcohol; slightly soluble in ether; very slightly soluble in chloroform; practically insoluble in water. |                       |
| Identification                   |  |                       |
| A. Infrared absorption <197K>    | The IR absorption spectrum of sample exhibits the same spectrum as Reference Standard. Absorptivities at 271 nm, calculated on the dried basis, do not differ by more than 3.0%.   |                       |
| B. Ultraviolet absorption <197U> |  |                       |
| C. Chemical Test                 |  |                       |
| Loss on drying                   | A red to red-violet color is produced.   |                       |
| Residue on ignition              | Not more than 1.0%.  |                       |
| Organic impurities               | The sum of the peak areas of peaks eluting before furosemide at 254 nm.  | : Not more than 0.5%. |
|                                  | The sum of the peak areas of peaks eluting after furosemide at 272 nm.   | : Not more than 0.5%. |
| Assay                            | 98.0 – 101.0% of Furosemide (C <sub>12</sub> H <sub>11</sub> ClN <sub>2</sub> O <sub>5</sub> S), calculated on the dried basis.  |                       |

|   |  |  |   |  |                       |
|---|--|--|---|--|-----------------------|
| Prepared by :<br><i>Benjawan Uboldech</i> , 08/07/19<br>Head of Raw Material Standard Section I | Reviewed by :<br><i>Benjawan Uboldech</i> , 09/07/19<br>Director of Raw Material Standard Division | <i>Pongy</i> , 09/07/19<br>Director of Microbiological Analysis Division | <i>Benjawan Uboldech</i> , 23/07/19<br>Director of Regulatory Compliance and Documentation Division | Approved by :<br><i>Benjawan Uboldech</i> , 24/07/19<br>Director of Quality Assurance Department | Eff. Date<br>15/08/19 |
|---|--|--|---|--|-----------------------|

# THE GOVERNMENT PHARMACEUTICAL ORGANIZATION

## RAW MATERIAL SPECIFICATION

|   |                                  |
|---|----------------------------------|
| <b>Title :</b> Furosemide USP (For injection dosage form) (Item No. 41032020) | <b>Spec. No. :</b> SP-AK30-F14/1 |
| <b>Reference(s) :</b> USP 39 p. 4059-4060                                     | <b>Rev. No. :</b> 06             |
| <b>Other Requirements :</b> GPO Specification                                 | <b>Page :</b> 2/3                |

### GPO Specification

| Test Items           | Specification   |
|----------------------|---|
| Heavy metals         | Not more than 20 ppm, Method II.                            |
| Bacterial endotoxins | Not more than 3.6 USP Endotoxin units per mg of furosemide. |

### Product Information

|                     |  |
|---------------------|--|
| Approved source (s) | Refer to current version of Approved Vendor List of Furosemide USP (For injection dosage form) (Item No. 41032020).    |
| Sampling plan       | 1. N Plan ( $\sqrt{N} + 1$ ) : for other tests.<br>2. 100% Identification.   |
| Testing procedure   | Tests to be performed as per current version of WI-AK30-F14/1.   |
| Storage condition   | To be stored in well-closed, light-resistant containers. Store at 25 °C, excursions permitted between 15 °C and 30 °C. |
| Retest period       | 1 year after first testing date.   |

|   |   |   |   |   |                       |
|---|---|---|---|---|-----------------------|
| Prepared by :<br>Benjawan Ubolakee, 08/07/19<br>Head of Raw Material Standard Section I | Reviewed by :<br>Tarnmu Linwunt, 09/07/19<br>Director of Raw Material Standard Division | Reviewed by :<br>P. 09/07/19<br>Director of Microbiological Analysis Division | Reviewed by :<br>23/07/19<br>Director of Regulatory Compliance and Documentation Division | Approved by :<br>Wichit Rungrojwong, 24/07/19<br>Director of Quality Assurance Department | Eff. Date<br>15/08/19 |
|---|---|---|---|---|-----------------------|

# THE GOVERNMENT PHARMACEUTICAL ORGANIZATION

## RAW MATERIAL SPECIFICATION

|   |                                  |
|---|----------------------------------|
| <b>Title :</b> Furosemide USP (For injection dosage form) (Item No. 41032020) | <b>Spec. No. :</b> SP-AK30-F14/1 |
| <b>Reference(s) :</b> USP 39 p. 4059-4060                                     | <b>Rev. No. :</b> 06             |
| <b>Other Requirements :</b> GPO Specification                                 | <b>Page :</b> 3/3                |

### History of changes

| Rev. No. | Description   | Effective date |
|----------|---|----------------|
| 04       | Update spec. เป็น USP 34  | 30/01/12       |
| 05       | Update spec. เป็น USP 39 เนื่องจากเอกสารมีอายุครบ 3 ปี จึงต้องทบทวน โดยเนื้อหาของ USP 34 และ USP 39 เหมือนกัน | 23/06/16       |
| 06       | เอกสารมีอายุครบ 3 ปี จึงต้องทบทวน โดยคงเนื้อหาเดิม USP 39   | 15/08/19       |

|  |  |   |   |  |   |                       |
|--|--|---|---|--|---|-----------------------|
| Prepared by :<br>S. Watanabe / 08/07/19<br>Head of Raw Material Standard Section I | Benjawan Ubolratana / 08/07/19<br>Head of Microbiological Analysis Section I | Reviewed by :<br>T. Watanabe / 09/07/19<br>Director of Raw Material Standard Division | P. Watanabe / 09/07/19<br>Director of Microbiological Analysis Division | Director of Regulatory Compliance and Documentation Division | Approved by :<br>R. Watanabe / 24/08/19<br>Director of Quality Assurance Department | Eff. Date<br>15/08/19 |
|--|--|---|---|--|---|-----------------------|